MetaVia reports 68% reduction in liver fat with DA-1726 in Phase 1 trial
MetaVia announced Phase 1 data showing a 68% placebo-adjusted reduction in liver fat and 13.5% weight loss, indicating strong clinical progress toward treating liver-related cardiometabolic diseases.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed